Radiology Takes Center Stage in Indian Diagnostics
India's diagnostic sector is shifting from its traditional pathology focus to a rising radiology segment. Radiology, vital for early disease detection via imaging like full-body scans and cancer screenings, offers higher revenue and deeper clinical insight. The significant capital needed for advanced radiology equipment creates substantial entry barriers, a key difference from previous industry models. The Indian radiology market is projected to grow at an 11-13% compound annual growth rate (CAGR) from FY24 to FY28, potentially reaching ₹62,000 crore by FY28. Current market data shows a clear divergence in investor sentiment and company valuations.
Vijaya Diagnostic Centre, a market leader, currently trades with a P/E ratio of approximately 55.2 to 68.29, well above the industry median P/E of 33.6. Despite this premium, its return on capital employed (ROCE) of 20.9% and return on equity (ROE) of 19.0% remain competitive and near industry averages. However, its stock has declined roughly 15% over the past year, with key moving averages indicating a downtrend. Conversely, Krsnaa Diagnostics trades at a considerable discount, with a P/E of 21.0 to 24.17, substantially below its peers and the industry median. Its ROCE and ROE also lag behind industry benchmarks. Krsnaa's stock price has fallen significantly from its 52-week high, with trading metrics suggesting a persistent downtrend. Suraksha Diagnostic occupies a middle ground, with a P/E around 33.59 to 37.13, near the industry median, but its ROCE and ROE are slightly below average. Suraksha has also faced headwinds, with its stock declining approximately 14% over the last year and trading below its key moving averages, signaling bearish sentiment. These price actions suggest market skepticism on the execution and profitability of radiology-heavy models, even as the sector expands. The BSE Healthcare index itself has seen a modest decline over the past year, indicating broader market pressures.
AI and Strategy Drive Company Fortunes
Technology, especially Artificial Intelligence (AI), is a key driver in radiology's expansion. Vijaya Diagnostic Centre uses AI software like "Augmento" to improve radiology reports and reach more remote areas. Krsnaa Diagnostics operates largely through a Public-Private Partnership (PPP) model, offering high-volume, discounted services. This approach, combined with significant upfront investment in radiology equipment, presents entry barriers and affects short-term earnings. Krsnaa is also planning a pathology expansion in Rajasthan, which could shift its revenue balance. Suraksha Diagnostic, a leader in Eastern India, is adopting AI for CT and MRI reports to speed up accuracy. It's also growing its network with a "Hub and Spoke" model and entering new regions to reduce reliance on West Bengal. These varied strategies—Vijaya's B2C and tech focus, Krsnaa's PPP volume play, and Suraksha's diversified AI adoption—are defining their market positions.
Valuation Gaps and Execution Risks Loom
Even with the promising radiology market outlook, significant risks remain. Krsnaa Diagnostics trades at much lower valuation multiples than Vijaya, Suraksha, and the industry median, a point needing careful examination. Despite analysts' "Buy" ratings and projections of over 90% upside potential, Krsnaa's stock trend is declining. Its reliance on the PPP model with long-term, discounted contracts could limit margin growth and be vulnerable to policy changes. Krsnaa also carries substantial debt, and its balance sheet shows a net cash position of over ₹-1.5 billion in the last 12 months, requiring close observation. Suraksha Diagnostic faces geographic concentration risk due to its heavy reliance on West Bengal for revenue, though expansion plans aim to address this. While Q3 FY26 revenue grew 30.3% year-on-year, net profit declined quarter-on-quarter. The recent resignation of its Group CFO may also introduce short-term operational uncertainties. Vijaya Diagnostic Centre, despite its strong B2C model and tech adoption, risks its premium valuation not being supported by rapid earnings growth compared to peers. Some analysts have issued "Reduce" or "Sell" ratings, citing concerns about its ability to maintain current valuations. Broader recent downturns in the healthcare sector also pose challenges for all companies.
Analysts See Growth Despite Risks
Analysts generally remain positive on the sector's prospects, with consensus ratings leaning towards "Buy" for both Vijaya Diagnostic Centre and Krsnaa Diagnostics. Average 12-month price targets indicate substantial upside potential for Krsnaa (up to +104%) and Vijaya (around +35%). Krsnaa's targets range from ₹682 to ₹1,230, showing a wide spread of analyst views. For Vijaya, price targets are between ₹950 and ₹1,300. Suraksha Diagnostic receives a more neutral analyst view, with one rating of "Neutral" and a price target of ₹285. Future growth will depend on these companies' success in investing in high-margin radiology, integrating AI, and managing competition and regulations. While the market growth outlook is positive, execution risks and valuation differences will heavily influence stock performance.